Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday, July 25, transferred an appeal over an award issued in an ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Alkermes today and set a price target of $42.00. The company’s shares opened today at $28.98. Take advantage of TipRanks Premium at 50% ...

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with ...